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838 Outcomes Research: Old Treatments, 
New Insights
Tuesday, March 09, 2004, 10:30 a.m.-Noon
Morial Convention Center, Room 265
10:30 a.m.
838-1 National Patterns of Spironolactone Prescription for 
Older Patients With Heart Failure and Left Ventricular 
Systolic Dysfunction Before and After RALES
Frederick A. Masoudi, Cary P. Gross, Yongfei Wang, Edward P. Havranek, Saif S. 
Rathore, JoAnne Micale Foody, Harlan M. Krumholz, Denver Health Medical Center, 
Denver, CO, Yale University School of Medicine, New Haven, CT
Background: In the RALES trial, published in September 1999, spironolactone improved
survival in selected patients with heart failure and left ventricular systolic dysfunction
(LVSD). Because of the risk of hyperkalemia, however, guidelines advise against use in
patients with K>5.0 mmol/l or creatinine>2.5 mg/dl.
Methods: Using data from the Centers for Medicare and Medicaid Services’ National
Heart Care Project, we studied Medicare patients > 65 years old with LVSD discharged
after hospitalization for heart failure in two time periods: 4/1998—3/1999 (before RALES
n= 9,758) or 7/2000—6/2001 (after RALES, n=9,468). We assessed changes in rates of
spironolactone prescription at discharge between periods in all patients and in strata
according to potassium and creatinine levels.
Results: Spironolactone prescriptions increased more than seven-fold between the two
samples (Table).Although prescription rates were higher in patients with creatinine <2.5
mg/dl, proportions of patients receiving spironolactone increased significantly in both cre-
atinine strata. Rates were similar in patients with normal potassium and those with rela-
tive hyperkalemia.
Conclusions: Spironolactone use nationwide increased markedly after the publication of
the RALES trial among older patients hospitalized with heart failure and LVSD. This use,
however, has extended to patients who are at a high risk for adverse outcomes. Current
patterns of practice may pose hazards to the safety of some patients.
10:45 a.m.
838-2 Rofecoxib Increases Cardiovascular Events in Arthritis 
Patients but Celecoxib and Nonspecific Nonsteroidal 
Anti-Inflammatory Drugs Do Not: Results From a Large 
New England Health Care Claims Database
Andrew Whelton, William M. Spalding, William B. White, Matthew J. Reeves, Sandy S. 
Suh, John G. Fort, Universal Clinical Research Center Inc, Hunt Valley, MD
Background: Treatment with cyclooxygenase-2 (COX-2) specific inhibitors may lead to
adverse cardiovascular (CV) events.
Objective: Determine relative risk (RR) of acute MI (AMI) or stroke associated with the
COX-2 specific inhibitors celecoxib and rofecoxib, and nonspecific NSAIDs in treated
hypertensive patients with osteoarthritis (OA) and/or rheumatoid arthritis (RA) in a large
New England healthcare claims database.
Methods: Population based retrospective analysis of >3 million patients aged >18 years
enrolled in a private medical insurance plan in the New England region of the US, from
January 1, 1999 - June 30, 2001. Enrollment, medical claims data and pharmacy claim
records were computer linked. NSAID and COX-2 specific users were identified using
NDC codes. Outcomes of interest were identified by ICD-9-CM codes 410-414 (AMI) or
430-436 (stroke). Sub-group analysis included prostaglandin-mediated antihypertensives
(ACEI, ARB, β-blocker). The incidence of CV events was estimated using Cox propor-
tional hazard time-to-event models adjusted for CV risk factors.
Results: RR for CV events with rofecoxib vs nonusers of NSAIDs was 2.45. No differ-
ences in RR were noted for celecoxib vs NSAIDS (p = 0.40) or nonusers (p = 0.06) and
NSAIDs vs non-users (p = 0.59). 
Conclusions: Rofecoxib significantly increases risk of AMI or stroke in treated 
hypertensive patients with OA or RA compared with nonusers. Patients receiving 
celecoxib, nonspecific NSAIDs, ACEI, ARB or β-blockers are at no enhanced risk.
11:00 a.m.
838-3 Safety and Efficacy of Glycoprotein IIb/IIIa Receptor 
Blockers in Patients With Chronic Renal Insufficiency 
Undergoing Contemporary Percutaneous Coronary 
Intervention
Mauro Moscucci, Dean E. Smith, Arthur Riba, Raj Goswami, Anthony DeFranco, Sanjaya 
Khanal, Michael O'Donnell, David Share, Kim A. Eagle, For the Blue Cross Blue Shield of 
Michigan Cardiovascular Consortium, University of Michigan, Ann Arbor, MI
Background: Chronic renal insufficiency (CRI) has been an exclusion criteria in clinical
trials of glycoprotein (Gp) IIb/IIIa receptor blockers. The objective of our study was to
evaluate safety and efficacy of GpIIb/IIIa blockers in patients with CRI undergoing con-
temporary percutaneous coronary intervention (PCI).
Methods: Data on 48,851 PCIs were collected in a regional consortium between 7/1997
and 5/2003. CRI was defined as baseline creatinine > 2 mg/dl. Patients with CRI receiv-
ing GpIIb/IIIa blockers (n=880) were compared with patients who did not (n=793). End-
points analyzed included hospital death, bleeding, and a composite major adverse
cardiac event (MACE) of death, emergency CABG, stroke and myocardial infarction (MI).
Bleeding was defined as any blood transfusion (tx) regardless the number of units.
Results: Patients receiving GpIIb/IIIa blockers were more likely to undergo emergency
PCI, and to undergo PCI for acute MI, shock and complex coronary stenosis (Table).
After adjustment for comorbidities, GpIIb/IIIa blockers were associated with a 36% risk
reduction of MACE (adjusted OR 0.64, 95% CI 0.43-0.96, p=0.03). No significant effect
was observed on mortality (adjusted OR 0.99, 95% CI 0.60-1.62, p=0.9) and tx (adjusted
OR 1.13, 95% CI 0.84-1.51, p=0.4).
Conclusions: PCI in patients with CRI continues to be associated with high in-hospital
morbidity and mortality. GpIIb/IIIa blockers in this patient population result in a significant
reduction in MACE without an increase in bleeding. 
11:15 a.m.
838-4 National Evaluation of Long-Term Adherence to Beta-
Blocker Therapy After Acute Myocardial Infarction in 
Patients With Commercial Health Insurance
Judith M. Kramer, Donald Fetterolf, John P. Charde, Richard Snyder, Daniel Checkman, 
Elizabeth DeLong, Nancy Allen LaPointe, Barbara Hoffman, Rhonda L. Arrington, Eric 
Peterson, Duke Clinical Research Institute, Durham, NC
Background: Despite a Class IA guideline recommendation for chronic use of beta-
blockers after acute myocardial infarction (MI), few studies have evaluated long-term
adherence to beta-blocker therapy after MI in a population with commercial insurance.
Methods: Using pharmacy claims data, nine health plans that are members of the Coun-
cil for Affordable Quality Healthcare (CAQH) performed a retrospective analysis of one-
year survivors of MI to measure cumulative population adherence to beta-blockers for 3,
6, 9, and 12 months after MI. Patients with MI in year 2000 were identified; beta-blocker
claims were determined for the subsequent 12 months. Health plans used common tech-
Rate
before RALES (n)
Rate
after RALES (n)
p
Total 3.0% (9,758) 21.3% (9,468) <0.0001
Creatinine
<2.5 mg/dL
3.1% (8,933) 22.0% (8,592) <0.0001
Creatinine
>2.5 mg/dL
1.9% (825) 14.1% (876) <0.0001
K <5.0 mmol/dL 3.0% (9,267) 21.2% (8,938) <0.0001
K >5.0 mmol/dL 2.7% (491) 22.8% (530) <0.0001
Treated Hypertensive 
Patients*
Non-users
N=1798
Celecoxib
N=1288
Rofecoxib
N=841
NSAIDs
N=1594
Years of exposure 3612.7 982.1 453.6 938.1
Relative Risk 1.00
(Reference)
1.35
(0.98, 1.86)
(p = 0.06)
2.45
(1.71, 3.51)
(p < 0.0001)
1.11
(0.74, 1.67)
(p = 0.59)
Sub-Group
ACE-I, ARB, β-Beta 
Blockersblockers
1.00
(Reference)
1.30
(0.90, 1.88)
(p = 0.17)
2.18
(1.41, 3.36)
(p = 0.0004)
0.91
(0.55, 1.50)
(p = 0.72)
* Adjusted for CV risk factors.
Variable (%) GpIIb/IIIa
yes (880)
GpIIb/IIIa
no (793)
p - value
Age 66.6 67.2 0.33
Female sex 33.6 41.1 0.002
PVD % 42.7 44.4 0.49
Type C Lesion 28.6 19.2 <0.001
Visible Thrombus 25.6 15.0 <0.001
Emergency Procedure 20.2 14.5 0.002
Acute MI 17.3 11.7 0.001
Cardiac Arrest 6.1 4.8 0.23
Cardiogenic shock 6.7 5.8 0.45
Outcomes
In-hospital mortality 6.9 6.4 0.68
MACE 9.2 10.7 0.30
Transfusion 18.6 17.2 0.47
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nical specifications; de-identified data were aggregated by CAQH to determine adher-
ence to beta blocker therapy overall, by region, and by type of health plan product.
Adherence was defined as claims for at least 75% “days supply” of beta-blocker during a
measurement interval.
Results: The study population included 15,070 patients from 44 states in 9 CAQH mem-
ber health plans (45% HMO/POS, 27% Medicare + Choice, 24% PPO, 4% Indemnity).
Adherence for 3, 6, 9, and 12 months was 55%, 52%, 49%, and 46%, respectively,
across all insurance products and regions. There was a pattern of declining adherence to
beta-blockers over time from discharge after MI in all insurance products and all geo-
graphic regions. Cumulative national population adherence for HMO/POS products for 3,
6, 9, and 12 months were 57%, 54%, 52%, and 49% respectively. Adherence for Medi-
care + Choice patients for the same intervals was lower: 49%, 46%, 42%, and 39%. In
comparison, 2001 HEDIS data estimated a mean of 92% for prescription of beta-blockers
within 7 days of discharge after MI.
Conclusion: Despite having prescription and commercial insurance coverage, less than
50% of this large population were still taking beta-blockers one year after MI. In order to
capture the survival benefit potentially afforded by beta-blockers, quality improvement ini-
tiatives need to focus on longer term outpatient adherence.
11:30 a.m.
838-5 Enrollment Disparities on the Basis of Age and Chronic 
Disease Burden in Cardiovascular Clinical Trials: Are 
Patients’ Decisions the Reason?
Anand Parekh, Neil R. Powe, Joel B. Braunstein, Johns Hopkins Medical Institutions, 
Baltimore, MD
Background: Randomized controlled trials have been criticized for enrolling select
groups of patients, while excluding those most representative of the population under
study. In cardiovascular disease, this concern implies inadequate representation of
patients who are older and have multiple comorbidities. We determined willingness to
participate (WTP) in a cardiovascular clinical trial among a community-based sample of
patients with these characteristics.
Methods: We approached 1440 randomly selected individuals from 13 Maryland-based
outpatient cardiology and internal medicine clinics to complete a brief self-administered
survey, which contained a 1-page description of an efficacy trial of a new drug for preven-
tion of myocardial infarction. We measured WTP on a 5-point Likert response scale (+
response = Very likely/ likely). Patients provided demographic and socioeconomic infor-
mation, along with a report of their comorbidity burden, measured by presence of condi-
tions included in the Deyo-Charlson case-mix severity index.
Results: Of 1132 patients eligible, 789 (70%) patients responded. Patients were mean
aged 54 ±16 (range 18-89) years, 51% female, and 35% black, with a median of 2 comor-
bidities (range 0-11). Older-aged patients (> 75 years)(n=79) were less WTP than
younger patients (19% vs. 36%, p<0.01). Patients with more extensive comorbidity, how-
ever, were no less WTP than those with less extensive comorbidity (WTP = 29% if no
comorbidity, 34% if 1 comorbidity, 35% if 2-4 comorbidites, 39% if > 5 comorbidites,
p=0.43). In multivariable logistic regression, after adjusting for race, gender, income, and
education, older age was associated with a 65% lower likelihood of WTP (OR, 95% CI =
0.35, 0.19-0.64; p=0.001), while each categorical increase in comorbidity was associated
with a 19% higher likelihood of WTP (1.19, 1.00-1.42; p<0.05).
Conclusion: While older age is independently associated with lower WTP in cardiovas-
cular clinical trials, more extensive comorbidity is not. These findings warrant consider-
ation in the design of future trials, which seek to adequately enroll cardiac patients who
are most representative of those encountered in routine clinical practice.
11:45 a.m.
838-6 The Impact of Prior Myocardial Infarction, Metabolic 
Syndrome, and High White Blood Cell Count on 
Coronary Heart Disease Mortality: The Multiple Risk 
Factor Intervention Trial (MRFIT) 18-Year Follow-Up 
Experience
Jerome D. Cohen, Ronald J. Prineas, Xin Zhi, Lynn E. Eberly, Lewis H. Kuller, James D. 
Neaton, The MRFIT Research Group, University of Minnesota, Minneapolis, MN, St. 
Louis University, St. Louis, MO
Background: Predictors of coronary heart disease (CHD) mortality include history of
myocardial infarction (MI), metabolic syndrome (MS) and inflammatory markers. MRFIT
data are used to examine their impact on CHD mortality over 18 years.
Methods: At the end of 6 years of follow-up there were a total of 11,357 men with mea-
sures of MI, MS and inflammatory markers. MI during the study ( n=208) was docu-
mented by records and /or ECG. Metabolic syndrome (n=4,761) was defined by ATP III
guidelines with at least 3 of the following present: obesity (BMI>30 kg/m² as a surrogate
for waist circumference), hypertension (blood pressure >130/85 mm Hg or on drugs), low
HDL cholesterol (<40 mg/dl), high fasting triglycerides (>150 mg/dl) and high fasting glu-
cose (>110 mg/dl). WBC above the median (6,900/µL) was used as a marker for inflam-
mation (n=5,679). Post-trial mortality was ascertained using the National Death Index.
Results: There were 1,257 CHD deaths after 18 years. The table shows the hazard
ratios for CHD mortality after adjustment for age, race, treatment group, smoking status
at entry and year 6 and average LDL cholesterol during follow-up. Similar results were
seen with total and CVD mortality.
Conclusions: The impact of each of these risk factors on CHD mortality is highly signifi-
cant and additive. These simple assessments can identify high risk patients who can be
targeted for appropriate medical management.
Hazard Ratios (HR) for CHD Mortality by Presence/Absence of MS,
WBC >6,900/µL and/or Prior MI 
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1153-67 Patient Attitudes in Clinical Trials: The PACT Survey
Milan Gupta, Blanche Aaron, Janice Burtcher, Nicoletta Bonafede, David Borts, 
Brampton Research Associates, Brampton, ON, Canada, William Osler Health Centre, 
Brampton, ON, Canada
Background: Little is known about patient attitudes towards informed consent and par-
ticipation in cardiovascular clinical trials (CT). We surveyed 430 consecutive participants
in 8 large in-patient (IP) and out-patient (OP) trials between 1998-2002 through a mailed
survey twice over 3 months.
Results: Of 430 participants, 37 (8.6%) died prior to study completion, and 242 (61.6%)
responded to the survey (69% male). Similar proportions had participated in IP and OP
CT (46.7% vs. 53.3%). The majority were 50-69 years old (59.8%), with 35.7% >age 69,
with no difference in age distribution between genders. The majority had a high school
(38.7%) or university degree (28.5%) and were unemployed or retired (66.9%). Most
patients had read the study consent form (87.6%), and 3.5% found the consent form too
difficult to understand. Women were more likely to feel pressured to join their CT than
men (16.2% vs. 5.5%, p=0.024). Side effects attributed to study drug were common
among women (27.5% vs. 11.9%, p=0.005), but early drug termination was similar
between genders (7.3% vs. 5.6%). The majority f (74.4%) were willing to participate in
future CT. Other differences noted:
Conclusions: CT participants are satisfied with informed consent and are willing to par-
ticipate in future trials.Women are more likely to feel pressured into joining, and to experi-
ence study-related side effects. The consent process is sub-optimal for participants of in-
patient clinical trials, and warrants further investigation.
1153-68 Do Patients With Heart Failure Have a Medically 
Accurate Mental Image of Their Illness (also known as 
Illness Representation)?
Nancy M. Albert, The Cleveland Clinic Foundation, Cleveland, OH
Background: HF self-care behaviors modulate symptoms, morbidity and prognosis but
adherence is inconsistent. Mental image of an illness or illness representation (REP)
influences coping and behavior. Attributes of REP that influence behavior in other chronic
conditions are identity (label, silent processes, symptoms), time-line (duration), conse-
quences (prognosis) and control (self-care actions). Medically inaccurate HF-REP may
negatively impact self-care adherence. There are no published reports of the medical
accuracy of patients HF-REP. Methods: 104 chronic systolic HF patients completed a 33-
item Likert scale of HF-REP statements. Patient sum score (range 33-132) determined
the level of HF-REP medical accuracy and item mean score (range 1-4) specified items
of low and high medical accuracy. Demographic and medical history data were used to
determine predictors of medically accurate HF-REP. Instrument Cronbach's alpha was
.8535; validity testing completed. Results: Mean age was 61.8 ± 13.13; 66% of patients
had HF for > 2 years. Mean sum score was 98.8, reflecting medically accurate HF-REP.
Thirty patients (28%) scored in the mixed medically accurate-inaccurate range (72-93)
MS WBC > 
6,900/ 
µL
MI No. 
Men
% 
Total
No.CHD 
Deaths
HR CHD 
Death
95% CI
- - - 3,395 (29.9) 265 1.0 
(reference)
- - + 47 (0.4) 13 3.7 (2.1-6.5)
- + - 3,084 (27.2) 302 1.2 (1.0-1.5)
+ - - 2,182 (19.2) 220 1.4 (1.2-1.7)
- + + 70 (0.6) 19 3.9 (2.4-6.4)
+ - + 32 (0.3) 12 5.6 (3.0-10.2)
+ + - 2,488 (21.9) 393 2.2 (1.9-2.6)
+ + + 59 (0.5) 33 10.7 (7.4-15.6)
% IP Participants % OP Participants p
Understood consent form 68.0 89.0 0.0002
Received copy of consent 49.1 70.5 0.0023
Felt pressure to join study 15.4 3.1 0.003
GP aware of participation 47.6 79.5 <0.0001
Would participate again 65.5 82.2 0.003
